Oligonucleotide Separations with RP Phases

HPLC, UHPLC

Oligonucleotide Separations with RP Phases

04 Feb, 2019

Published over 7 years ago. See the latest and most current information on HPLC, UHPLC.

Therapeutic oligos represent an important area of research in the pharmaceutical industry today. These drug candidates are typically 8-50 nucleotides long and contain single-stranded DNA or RNA. Oligonucleotides are typically analysed using ion-pairing chromatography. Oligonucleotides are easily degraded via phosphodiester-cleaving enzymes. However, with a thiophosphate modified phosphate group, the stability significantly increases. Phosphorothioate modified oligos will have a stereocenter at each modified phosphate group, leading to 2n-1 diastereomers, all with an individual retention time in the chromatography. For a 20-nucleotide long oligo, that’s 524 288 species present. The partial resolution of these species results in peak broadening, further complicating chromatographic separation. To resolve the problem, ion-pairing agents with longer alkyl chains can be used.

In a study of the influence of stationary phase and ion-pairing agent on the separation of oligos, Kromasil Phenyl showed to be a very good choice when separating oligonucleotides in general, exhibiting very sharp peaks, and good selectivity.

View these applications on www.kromasil.com/oligos.

Latest News

Explore Our Other Sites

Labmate Online
Metrohm launches OMNIS IC: a new benchmark in ion chromatography
Explore more Arrow
Envirotech Online
Phenol on the ground: what a COMAH prosecution shows about soil data as evidence
Explore more Arrow
Pollution Solutions Online
Pump and mixer service at paper mill set to reach 40 years
Explore more Arrow
Petro Online
Hydrogen sulphide deaths expose the gaps in gas detection during non-routine work
Explore more Arrow